| Literature DB >> 27515403 |
Bao Yi1, Liang Chen1, Renna Sa1, Ruqing Zhong1, Huan Xing1, Hongfu Zhang2.
Abstract
BACKGROUND: High concentrations of atmospheric ammonia are one of the key environmental stressors affecting broiler production performance, which causes remarkable economic losses as well as potential welfare problems of the broiler industry. Previous reports demonstrated that high levels of ammonia altered body fat distribution and meat quality of broilers. However, the molecular mechanisms and metabolic pathways in breast muscle altered by high concentrations of ambient ammonia exposure on broilers are still unknown.Entities:
Keywords: Ammonia; Breast muscle; Broiler (Gallus gallus); Meat quality; RNA-Seq
Mesh:
Substances:
Year: 2016 PMID: 27515403 PMCID: PMC4982197 DOI: 10.1186/s12864-016-2961-2
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Effects of atmospheric ammonia on growth performance and body fat distribution in broiler chickens
| Groups | ||
|---|---|---|
| Control | Treatment | |
| ADG (g/d) | 99.41 ± 10.08a | 67.92 ± 12.68b |
| ADFI (g/d) | 158.42 ± 5.78a | 125.56 ± 1.50b |
| FCR (g feed/g weight gain) | 1.64 ± 0.18b | 1.80 ± 0.25a |
| Breast muscle (%) | 23.61 ± 1.06 | 22.09 ± 2.28 |
| Fat in breast muscle (%) | 1.14 ± 0.18a | 0.78 ± 0.14b |
| Liver (%) | 19.53 ± 1.60 | 19.32 ± 1.90 |
| Fat in liver (%) | 5.41 ± 1.18a | 3.09 ± 0.17b |
| Abdominal fat (%) | 1.62 ± 0.10b | 2.05 ± 0.45a |
Values within a row not sharing a common superscript letter indicate significant difference between groups at P < 0.05. Numbers are mean ± S.D
ADG average daily gain, ADFI average daily feed intake, FCR feed conversion ratio
a, b within a row indicate significant difference between groups at P <0.05
Summary statistics for sequence quality and alignment information of six breast muscle samples in two groups
| Sample | C_1 | C_2 | C_3 | T_1 | T_2 | T_3 |
|---|---|---|---|---|---|---|
| Group | Control | Control | Control | Treatment | Treatment | Treatment |
| Raw reads | 73,139,016 | 73,988,890 | 70,579,138 | 74,086,562 | 82,677,190 | 100,025,614 |
| Clean reads | 69,375,390 | 70,089,536 | 66,879,214 | 70,162,270 | 78,368,448 | 94,553,606 |
| Valid ratio (%) | 94.81 % | 94.68 % | 94.71 % | 94.66 % | 94.75 % | 94.49 % |
| Q30 (%) | 94.90 % | 94.75 % | 94.79 % | 95.04 % | 95.11 % | 94.92 % |
| GC content (%) | 51.50 % | 51.50 % | 51.50 % | 51.50 % | 51.50 % | 51.50 % |
| Total mapped reads | 49,236,780 | 49,313,882 | 47,427,718 | 50,794,372 | 57,048,473 | 69,576,797 |
| Uniquely mapped reads | 45,869,880 | 45,818,693 | 44,268,019 | 47,090,588 | 52,708,435 | 64,514,418 |
| Multiple mapped reads | 3,366,900 | 3,495,189 | 3,159,699 | 3,703,784 | 4,340,038 | 5,062,379 |
| Mapping rate (%) | 70.97 % | 70.36 % | 70.92 % | 72.40 % | 72.80 % | 73.58 % |
Fig. 1The percentage of reads mapped to exonic, intronic and intergenic regions
Fig. 2Volcano plot. Red dots (Up) represent significantly up-regulated genes (P < 0.05, fold change ≥ 2); green dots (Down) represent significantly down-regulated genes (P < 0.05, fold change ≤ 0.5); black dots (No) represent insignificantly differential expressed genes
Top 10 down- and up-regulated genes in treatment group compared to control group
| Gene ID | Gene symbol | Fold change |
|---|---|---|
| Down-regulated genes | Down | |
| NM_001199909.1 |
| 30.4 |
| XM_004940680.1 |
| 23.5 |
| NM_001277411.1 |
| 18.1 |
| NM_001167752.2 |
| 17.3 |
| XM_004937471.1 |
| 13.0 |
| XM_004937841.1 |
| 12.4 |
| XM_416332.4 |
| 11.8 |
| NM_001005431.1 |
| 11.4 |
| NM_001030956.1 |
| 9.8 |
| XM_416965.4 |
| 8.5 |
| Up-regulated genes | Up | |
| XM_004950318.1 |
| 11.4 |
| XM_419014.3 |
| 7.0 |
| XM_004938015.1 |
| 5.8 |
| XM_417174.4 |
| 4.8 |
| NM_204672.1 |
| 4.8 |
| NM_001007477.3 |
| 4.0 |
| XM_004944616.1 |
| 3.6 |
| XM_419574.4 |
| 3.4 |
| NM_001001766.1 |
| 3.4 |
| XM_004946388.1 |
| 3.4 |
PDK4, pyruvate dehydrogenase kinase, isozyme 4, FHL1 four and a half LIM domains 1 CA3, carbonic anhydrase III, muscle specific, MB myoglobin, PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, MYBPC1 a myosin binding protein C, slow type, transcript variant X1, MYBPC1 b myosin binding protein C, slow type, transcript variant X2, FKBP5 FK506 binding protein 5, FBXO32 F-box protein 32, METTL21C methyltransferase like 21C, LOC101748351 spindle and kinetochore-associated protein 1-like, SBK2 SH3-binding domain kinase family, member 2, CYB5R3 cytochrome b5 reductase 3, DCUN1D5 DCN1, defective in cullin neddylation 1, domain containing 5, SNCG synuclein, gamma (breast cancer-specific protein 1), LOC396531 parvalbumin, LOC770936 serine/threonine-protein kinase SRPK3-like, C1ORF96 chromosome 3 open reading frame, human C1orf96, LIMS1 LIM and senescent cell antigen-like domains 1, DNAJC30 DnaJ (Hsp40) homolog, subfamily C, member 30
Fig. 3The relative expression level (in FPKM) of differentially expressed genes between control and treatment groups. The X-axis is sample expression pattern in different concentrations of ammonia exposed groups. The first three samples are in control group; the latter three samples are in treatment group. The Y-axis is the gene clusters across groups
Fig. 4qRT-PCR validation of differential expressed genes from breast muscle of 42-day-old AA broilers. GAPDH was used as an internal control, and data are presented as fold change (n = 3 per group)
Fig. 5Gene ontology (GO) annotation of differentially expressed genes. GOTERM_BP, biological process; GOTERM_CC, cellular component; GOTERM_MF, molecular function
Fig. 6KEGG Pathway analysis of differentially expressed genes
Significantly enriched pathways for differential expressed genes
| Pathway name | Enriched genes |
|
|---|---|---|
| Steroid biosynthesis |
| 0.00 |
| PPAR signaling pathway |
| 0.03 |
DHCR24 24-dehydrocholesterol reductase, DHCR7 7-dehydrocholesterol reductase, HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7, LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase), ACSL1 acyl-CoA synthetase long-chain family member, CPT-1A carnitine palmitoyltransferase 1A (liver), CD36 CD36 molecule (thrombospondin receptor), SLC27A1 solute carrier family 27 (fatty acid transporter), member 1